Related by context. All words. (Click for frequent words.) 68 progression TTP 67 disease progression TTP 66 patients evaluable 65 relapsed MM 65 RECIST criteria 65 biochemical relapse 65 bortezomib refractory 65 interquartile range 65 neurologic progression 64 timepoints 64 KRAS mutations occur 64 hours postdose 64 resected pancreatic cancer 64 atazanavir ritonavir 63 tumor progression TTP 63 evaluable subjects 63 CCyR 63 eculizumab therapy 63 underwent liver transplantation 63 CR nPR 63 % CI #.#-#.# [003] 63 prior chemotherapy regimens 63 Partial Responses 63 mg/m2 dose 63 hemodialysis patients 63 Kaplan Meier 63 Secondary endpoints include 62 intermittent dosing 62 recurrent VTE 62 intravenous diuretics 62 ICD therapy 62 evaluable 62 heavily pretreated 62 remission CR 62 postintervention 62 mg kg dose 62 Kaplan Meier estimates 61 genotypic resistance 61 achieved sustained virological 61 PASI scores 61 evaluable patients 61 posttreatment 61 CRp 61 complete cytogenetic response 61 treatment naive genotype 61 interferon ribavirin 61 achieved CCyR 61 dose escalation phase 61 posttransplant 61 rituximab refractory 61 pCR 61 biochemical recurrence 61 antiretroviral naive 61 APTIVUS r 61 CR CRu 61 underwent resection 61 Kaplan Meier analysis 61 plus dexamethasone 61 dosing cohort 61 seroprotection 61 virological response 61 desvenlafaxine succinate 60 hepatitis C genotype 60 octreotide LAR 60 EDSS scores 60 chlorambucil 60 free survival PFS 60 serum HCV RNA 60 certolizumab 60 interquartile range IQR 60 prospectively stratified 60 clinically meaningful improvement 60 preintervention 60 methotrexate monotherapy 60 dose cohort 60 PSA nadir 60 EDSS score 60 corticosteroid dose 60 underwent surgical resection 60 pegylated IFN 60 moderately emetogenic 60 osteoporotic vertebral compression fractures 60 hsCRP levels 60 acromegalic patients 60 recurrent glioblastoma multiforme 60 androgen suppression 60 QTcF 60 NATRECOR R 60 virologic failure 60 NNT = 60 HBeAg negative patients 60 rindopepimut 60 detectable HCV RNA 60 PSADT 60 NATRECOR ® 60 adjuvant cisplatin 60 sustained virological response 59 prespecified 59 tapentadol ER 59 pegylated interferon alfa 2b 59 liver transplant recipients 59 dosing cohorts 59 retrospective cohort 59 MCyR 59 iniparib BSI 59 PegIFN RBV 59 tumor histology 59 q#d 59 crizotinib PF # 59 viral kinetics 59 perioperative mortality 59 recurrent atrial fibrillation 59 induction regimen 59 antiretroviral naïve 59 biliary tract cancer 59 Kaplan Meier survival 59 Flu Cy 59 perioperatively 59 prospectively defined 59 adjuvant tamoxifen 59 peginterferon 59 FOLFOX4 59 virologic breakthrough 59 morphometric vertebral fractures 59 operable breast cancer 59 postprocedure 59 angiographic outcomes 59 Tumors shrank 59 alteplase 59 locoregional disease 59 standard chemotherapy regimen 59 RECIST Response Evaluation Criteria 59 relapsed MCL 59 CIMZIA ™ 59 serum HBV DNA 59 EGFR mutation positive 59 rebleeding 59 mg administered orally 59 Engerix B 59 low dose Iluvien 59 CIMZIA TM 59 undetectable HCV RNA 59 -#.# log# copies mL 59 serum cortisol 58 Free Survival PFS 58 recurrent venous thromboembolism 58 median PFS 58 glycosylated hemoglobin levels 58 achieved ACR# 58 HbA 1c levels 58 % CI #.#-#.# [007] 58 KRAS status 58 placebo dexamethasone 58 thrombocytopenic 58 MVax 58 mg/m2/day 58 low dose cytarabine 58 hepatorenal syndrome 58 baseline LDH 58 pharmacokinetics PK 58 divalproex sodium 58 Median survival 58 cisplatin chemotherapy 58 teriflunomide 58 doxorubicin docetaxel 58 postop 58 nondiabetic patients 58 cytogenetic response 58 preoperative chemotherapy 58 glycated hemoglobin levels 58 Response Evaluation Criteria 58 Wisconsin Sleep Cohort 58 clodronate 58 decitabine 58 hip resurfacing arthroplasty 58 Doxil ® 58 reinfarction 58 RRMS patients 58 serum phosphate 58 glomerular filtration 58 HBeAg seroconversion 58 PREZISTA r 58 mg m² 58 HbA1C levels 58 virologic response 58 #mg/day [001] 58 Viral load 58 RECIST 58 randomized multicenter trial 58 rt PA 58 antiangiogenic therapy 58 Index CDAI 58 DLQI 58 nonvertebral fractures 58 rtPA 58 PNH patients 58 adjunctive placebo 58 alicaforsen enema 58 radiographic progression 58 complete cytogenetic 58 Kaplan Meier method 58 5-FU/LV 58 dexmedetomidine 58 mcg albinterferon alfa 2b 58 metastatic GIST 58 rFVIIa 58 Median progression 58 baseline HbA1c 58 leukocyte count 58 Pharmacokinetic parameters 58 RSV hospitalizations 58 SIMPADICO 58 symptomatic VTE 58 mg/m2 IV 58 % Confidence Interval 58 mcg dose 58 complete remissions 58 postoperatively 57 cisplatin vinorelbine 57 comparator arm 57 achieving PASI 57 secondary efficacy endpoint 57 response CCyR 57 TURBT 57 infliximab therapy 57 EBMT criteria 57 undetectable viral 57 F FDG PET 57 confirmed CCyR 57 Hb A1C 57 ancrod 57 median survivals 57 hepatectomy 57 perioperative morbidity 57 undetectable HBV DNA 57 Pegasys plus Copegus 57 postoperative chemotherapy 57 FOLFIRI alone 57 randomized Phase 2b 57 treatment naïve genotype 57 Lupuzor ™ 57 salivary cortisol 57 HCV RESPOND 2 57 locoregional 57 intravenous cyclophosphamide 57 KRAS mutant tumors 57 histological subtype 57 aneurysmal subarachnoid hemorrhage 57 beta blocker therapy 57 dose dexamethasone 57 binary restenosis 57 IV malignant melanoma 57 mutated KRAS 57 placebo controlled dose escalation 57 chronic GVHD 57 tipranavir r 57 dalteparin 57 CPAP adherence 57 virologic 57 undergone splenectomy 57 QRS duration 57 naïve HCV 57 oral rivaroxaban 57 CMV disease 57 response pCR 57 reintervention 57 dose regimens 57 hemoglobin A1c levels 57 null responder 57 Folfox 57 nonvertebral fracture 57 adult chronic ITP 57 titration phase 57 oral diclofenac 57 debulking surgery 57 pamidronate 57 HIV HCV coinfected 57 oblimersen 57 ruptured aneurysms 57 8mg/kg 57 histrelin 57 methotrexate therapy 57 PRECiSE 57 dose cohorts 57 severe exacerbations 57 dosing interval 57 CIMZIA TM certolizumab pegol 57 TLUS 57 cytoreduction 57 intracranial hemorrhage ICH 57 VELCADE melphalan 57 null responders 57 ZOLINZA 57 splenectomized patients 57 Solid Tumors criteria 57 HER2 expression 57 subcutaneous PRO 57 achieved sustained virologic 57 lymphocytosis 57 NIHSS score 57 stage IIIb IV 57 Secondary endpoints included 57 Crohn Disease Activity 57 preoperative PSA 57 % CI #.#-#.# [008] 57 colorectal liver metastases 57 definite stent thrombosis 57 DLTs 57 NMIBC 57 metastatic kidney 57 Subgroup analysis 57 disease progression 57 HCV SPRINT 57 mitoxantrone plus 57 seropositivity 57 sustained virologic response 57 dosage regimens 57 Xelox 57 Operative mortality 57 SCIg 57 curability 57 bolus dose 57 β blockers 57 relapsed AML 57 topotecan 57 MACCE 57 locoregional recurrence 57 MMSE score 57 #mg QD [001] 57 recurrent GBM 57 liver resection 57 NYHA functional class 57 XIENCE V PROMUS Stent 57 tumor resection 57 REYATAZ r arm 57 FOSRENOL ® 57 mRCC 57 oral FTY# 57 virologic response EVR 57 Median PFS 57 serum aminotransferase levels 57 GnRH agonist 57 dose titration 57 chemoradiotherapy 57 CYPHER Stent 57 salmeterol fluticasone 57 clopidogrel therapy 57 colorectal adenoma 57 systolic dysfunction 56 antibody titer 56 HSCT 56 acute STEMI 56 ximelagatran 56 chronic HBV 56 metastatic lung cancer 56 DAS# CRP 56 Aptivus ® 56 blastic phase 56 graft occlusion 56 gemcitabine carboplatin 56 achieved PASI 56 primary patency 56 galiximab 56 RE LY ® 56 ascending dose 56 surgical debulking 56 ribavirin therapy 56 Postoperatively 56 postdose 56 postoperative mortality 56 azacitidine 56 #mg QD [002] 56 maximal dose 56 ipsilateral stroke 56 IOP lowering 56 ACR# response 56 paroxysmal AF 56 ALT elevation 56 imatinib therapy 56 anemia hemoglobin 56 ACTEMRA TM 56 virological failure 56 DAS# remission 56 IU ml 56 MitraClip device 56 moderate renal impairment 56 relapsing remitting MS RRMS 56 mg QD 56 mIU ml 56 mg ustekinumab 56 estramustine 56 PRADAXA #mg 56 T1DM 56 lumiliximab 56 timepoint 56 ischemic cardiomyopathy 56 glycosylated hemoglobin HbA1c 56 Solid Tumors RECIST 56 HIV RNA 56 mITT population 56 nonoperative treatment 56 placebo controlled clinical trials 56 #mg dose [002] 56 argatroban 56 randomized multicenter Phase III 56 randomized blinded 56 intravenous IV infusion 56 ALT flares 56 oral anticoagulation 56 asymptomatic carotid stenosis 56 lung metastases 56 FFNS 56 antithrombotic therapy 56 hour bronchodilation 56 LPV r 56 Zometa hazard 56 leukemia AML 56 retrospective observational study 56 anagrelide 56 QT intervals 56 HBeAg positive patients 56 vidofludimus 56 plasma HCV RNA 56 allogeneic transplantation 56 aldosterone antagonists 56 adverse cytogenetics 56 virological suppression 56 chemo radiotherapy 56 amoxicillin clavulanate 56 nadroparin 56 LEXIVA r 56 BoNTA 56 postdischarge 56 cinacalcet 56 bupropion SR 56 experienced virologic failure 56 perioperative complications 56 lymphocyte count 56 pharmacokinetic characteristics 56 venlafaxine XR 56 immunosuppressive regimen 56 serum clusterin levels 56 colorectal cancer liver metastases 56 BARACLUDE ® 56 maximally tolerated dose 56 mCRC patients 56 #mg/m# [002] 56 nonmetastatic 56 postoperative complication 56 achieve sustained virologic 56 gemcitabine cisplatin 56 intravenous tPA 56 thrombotic complications 56 mg/m2 cohort 56 apremilast 56 curative resection 56 graft dysfunction 56 HUMIRA achieved PASI 56 metastatic renal cell 56 Retreatment 56 Q#IR 56 follicular lymphomas 56 rapid virological response 56 oxycodone CR 56 mL/min/#.# m 2 56 aged ≥ 56 plasma cortisol 56 IFN alfa 56 telaprevir dosed 56 dosing intervals 56 serum magnesium 56 trastuzumab Herceptin ® 56 APTIVUS R 56 nonmetastatic prostate cancer 56 SCr 56 receiving VICTRELIS 56 TNF antagonist 56 de novo AML 56 -#.# log# 56 femoral shaft fracture 56 seroconversion 56 elevated troponin 56 BR.# 56 NPH insulin 56 FluCAM 56 lipid lowering therapy 56 clinically meaningful improvements 56 BENICAR HCT 56 pyridostigmine 56 pancreatic carcinoma 56 demonstrated clinically meaningful 56 Index CDAI score 56 XIENCE V demonstrated 56 plus methotrexate 56 oral clodronate 56 rituximab Rituxan 56 bowel resection 56 echocardiographic parameters 56 refractory CLL 56 RGT arm 56 death reinfarction 56 everolimus eluting stents 56 nadolol 56 serum phosphorous 56 vincristine doxorubicin 56 sUA 56 Target Lesion Revascularization TLR 56 bi ventricular pacing 56 rALLy trial 56 allogeneic SCT 56 UPDRS scores 56 annualized relapse 56 chemoradiation therapy 56 ACR Pedi 56 nicardipine 56 doxorubicin cyclophosphamide 56 XELOX 56 hypofractionated radiation 55 underwent CABG 55 Stage IIB 55 microbiologically evaluable 55 Kinoid 55 enzastaurin 55 rimonabant #mg 55 Partial Response 55 cART 55 generalized edema 55 neutrophil counts 55 MAGE A3 ASCI 55 repeat paracentesis 55 #mg BID [001] 55 mmHg systolic 55 A1c levels 55 adefovir treated 55 attain statistical significance 55 nonsquamous 55 malignant neoplasm 55 FluCAM arm 55 partial remissions 55 lanthanum carbonate 55 androgen deprivation 55 3mg/kg 55 serum lipid levels 55 EMPHASIS HF trial 55 visceral metastases 55 refractory CTCL 55 rapid virologic response 55 peg interferon 55 ribavirin RBV 55 nucleoside naive patients 55 mesalamine granules 55 nadir CD4 cell 55 normothermic 55 azilsartan medoxomil 55 pretransplant 55 peginterferon alfa 2a #KD 55 alanine aminotransferase ALT 55 adenotonsillectomy 55 μmol L 55 chest radiographs 55 coronary artery bypass grafts 55 pegylated interferon alpha 55 hypofractionated 55 dose melphalan 55 peginterferon alfa 2a 55 TroVax ® 55 subcutaneous methylnaltrexone 55 PEG IFN 55 chronic HCV genotype 55 nab paclitaxel 55 adenoma recurrence 55 SUVmax 55 adalimumab Humira 55 ponatinib 55 ruboxistaurin 55 #mg ATC 55 GAMMAGARD 55 glycemia 55 electrical cardioversion 55 intact parathyroid hormone 55 intravenous dosing 55 docetaxel chemotherapy 55 endoscopic remission 55 variceal bleeding 55 mmHg diastolic 55 plus gemcitabine 55 baseline FEV 55 lamivudine refractory patients 55 TMC# r 55 posaconazole 55 androgen ablation 55 μg dose 55 STRIDE PD 55 aromatase inhibitor therapy 55 spirometric 55 inhospital 55 KRAS wild 55 corrected QT interval 55 stage IIIB IV 55 invasive aspergillosis 55 Diamyd r 55 interstitial brachytherapy 55 ER CHOP 55 liver biopsies 55 recurrent myocardial infarction 55 laxation 55 pegylated liposomal doxorubicin 55 paclitaxel eluting stents 55 virologic suppression 55 inhaled budesonide 55 ug dose 55 peak plasma concentrations 55 urinary N telopeptide 55 hemodynamically stable 55 liver metastases 55 recurrent metastatic 55 IFN beta 55 IFN α 55 undergoing bariatric surgery 55 Insulin PH# 55 inhaled corticosteroid therapy 55 pharmacodynamic PD 55 tamoxifen therapy 55 daily subcutaneous injections 55 Virologic 55 overt nephropathy 55 oncologic outcomes 55 observational cohort study 55 clevidipine 55 HER2 overexpression 55 activated partial thromboplastin 55 idraparinux 55 pegylated interferon ribavirin 55 ofpatients 55 serum uric acid 55 plus prednisone 55 PASI score 55 asthma exacerbation 55 chronic periodontitis 55 gefitinib Iressa 55 lumbar spine BMD 55 noninferior 55 NHANES III 55 epoetin alpha 55 ispinesib administered 55 Breslow thickness 55 low dose dexamethasone 55 pretreatment baseline 55 BEXXAR Therapeutic Regimen 55 DASISION 55 prognostic variables 55 troponin T 55 inhaled iloprost 55 severe neutropenia 55 NIHSS 55 serum phosphate levels 55 remission induction 55 induce remission 55 nonadherence 55 intradermal injections 55 pimecrolimus cream 55 heavily pretreated patients 55 reduce serum phosphate 55 omega interferon 55 temozolomide TMZ 55 diagnostic angiography 55 abacavir lamivudine 55 YERVOY 55 venous thromboembolic disease 55 chemotherapy docetaxel 55 Platelet counts 55 plasma uric acid 55 noninferiority 55 anthracycline taxane 55 sirolimus eluting stents 55 symptomatic paroxysmal AF 55 K ras mutations 55 nucleoside naive 55 p = NS 55 care regimens CCR 55 pegylated interferon alfa 55 hepatic metastases 55 deep venous thromboses 55 Febrile neutropenia 55 microbiological eradication 55 recurrent malignant glioma 55 serum calcium levels 55 lamivudine monotherapy 55 Teriflunomide 55 fluvastatin 55 postprandial glycemia 55 DAPT 55 EURIDIS 55 Thal Dex 55 ECOG PS 55 Ceplene/IL-2 55 undetectable hepatitis C 55 prospective observational cohort 55 seminal vesicle invasion 55 DEB# 55 liver histology 55 indolent NHL 55 cerebral vasospasm 55 NNRTI resistant virus 55 adalimumab 55 transrectal ultrasound guided 55 multivariable analysis 55 radiochemotherapy 55 pharmacokinetic PK profile 55 REMINYL ® 55 Tasigna prolongs 55 fluticasone salmeterol 55 ToGA 55 CHOP chemotherapy 54 Jevtana 54 clot busting therapy 54 irinotecan cisplatin 54 RLAI 54 postoperative AF 54 dose proportionality 54 bronchopulmonary dysplasia BPD 54 VFEND 54 previously untreated follicular 54 virologic responses 54 receiving APTIVUS r 54 platelet reactivity 54 anti coagulant therapy 54 calculated creatinine clearance 54 mean ± SEM 54 EGFR TKI 54 glufosfamide 54 postoperative atrial fibrillation 54 solifenacin 54 MGd 54 inotropes 54 GOUT 54 distant metastasis 54 EXJADE 54 neoadjuvant radiation 54 ‰ ¥ 54 CK # plasma concentrations 54 hemoglobin A1c HbA1c 54 maximal doses 54 pulmonary arterial 54 HBV DNA levels 54 postinjury 54 serum urate levels 54 radiographic outcomes 54 hematopoietic cancers 54 Cimzia TM 54 MIRAPEX 54 Secondary endpoints 54 pain palliation 54 GH deficiency 54 QTc prolongation 54 undergoing coronary angiography 54 CHAMPION PCI 54 metastatic RCC 54 NovoTTF 54 nulliparous women 54 liver metastasis 54 Peg IFN 54 C difficile infection 54 papillary renal cell carcinoma 54 infliximab monotherapy 54 Triapine R 54 tipranavir ritonavir 54 multivariable logistic regression 54 erlotinib Tarceva 54 Lung transplantation 54 neoadjuvant 54 symptomatic intracranial hemorrhage 54 extracolonic findings 54 prespecified secondary 54 IQR 54 mucosal healing 54 Fludara 54 dacarbazine chemotherapy 54 elevated IOP 54 Timed Walk 54 ejection fractions 54 nucleotide analog 54 plus ribavirin 54 eribulin mesylate 54 antiarrhythmic drug 54 estimated GFR 54 microgram kg 54 segment binary restenosis 54 fulvestrant 54 % CI #.#-#.# [005] 54 fibrinolysis 54 unresectable stage 54 oral Hycamtin 54 confidence intervals CIs 54 proliferative retinopathy 54 intravascular hemolysis 54 romiplostim 54 fraction LVEF 54 multicenter randomized controlled 54 Circulating tumor cells 54 axitinib 54 forodesine 54 ExTRACT TIMI 54 undetectable viral load 54 Insulin detemir 54 receiving highly emetogenic 54 nonoperative 54 immunosuppression therapy 54 GVAX 54 nonobstructive CAD 54 juvenile idiopathic arthritis 54 Decitabine 54 subcutaneous infusion 54 tolerability profiles 54 cGy 54 systolic function 54 paliperidone ER 54 relapsed SCLC 54 weekly subcutaneous injections 54 recurrent GBM patients 54 alemtuzumab treated 54 Charlson comorbidity index 54 fibrinolytic therapy 54 FOLFOX 54 ZACTIMA 54 Preoperatively 54 Ishak fibrosis score 54 L PPDS 54 postsurgical 54 non splenectomized 54 plasma leptin 54 docetaxel Taxotere ® 54 inotropic 54 FOLFOX4 alone 54 HIV uninfected 54 thromboprophylaxis 54 chemoradiation 54 intravenous tissue plasminogen 54 Follicular Lymphoma 54 HBeAg negative 54 LV dysfunction 54 INVEGA ® 54 Zemplar Capsules 54 neoadjuvant therapy 54 patients 54 CMV reactivation 54 plasma glucose concentrations 54 golimumab CNTO 54 treprostinil 54 SERCA2a 54 highly emetogenic 54 RSD# oral 54 transarterial 54 baseline CD4 54 μg liter 54 ICD implantation 54 intravitreal injections 54 angiographic restenosis 54 confidence interval #.#-#.# 54 CLL SLL 54 onset atrial fibrillation 54 imipenem 54 Kaplan Meier curves 54 mcg BID 54 relapsing multiple sclerosis 54 cirrhotic patients 54 hip BMD 54 5-fluorouracil/leucovorin 54 XR NTX 54 hepatic resection 54 oral methylnaltrexone 54 cEVR 54 MADIT II 54 neoadjuvant treatment 54 placebo controlled clinical 54 de novo kidney transplant 54 briakinumab 54 nonrandomized 54 gout flares 54 treat NNT 54 Baseline characteristics 54 serum urate 54 sUA levels 54 COPD exacerbation 54 dose cytarabine 54 estimated glomerular filtration 54 relapsing MS 54 QALE 54 pegylated interferon peg IFN 54 confidence interval CI 54 melphalan prednisone 54 VT VF 54 demonstrated antitumor activity 54 fasting triglyceride levels 54 riociguat 54 candidemia 54 p = .# [002] 54 IU mL 54 hematologic malignancy 54 TIMP 1 54 creatinine clearance 54 Scale EDSS 54 darunavir r 54 serum concentrations 54 inhaled nitric oxide 54 oral prednisolone 54 mild renal insufficiency 54 anti leukemic 54 IEQ kg 54 eosinophilic asthma 54 protease inhibitor PI 54 therapeutic regimens 54 AGILECT R 54 pharmacodynamic effects 54 bronchodilation 54 splenectomized 54 HORIZONS AMI trial 54 viral kinetic 54 prostate cancer CaP 54 #mg/day [002] 54 gadolinium enhanced 54 randomized controlled trials RCTs 54 SVR# 54 remifentanil 54 multivariate analyzes 54 pomalidomide 54 ibandronate 54 platelet inhibition 54 mcg QD 54 unstable angina pectoris 54 rimonabant #mg/day 54 Pemetrexed 54 atherosclerotic renal artery stenosis 54 decompensated heart failure 54 aminotransferase levels 54 ADVEXIN efficacy 54 FOLFIRINOX 54 #mmHg [001] 54 serum PTH 54 aldosterone antagonist 54 abiraterone acetate 54 tumor recurrence 54 mg BID dose 54 plasma glucose levels 54 VcMP 54 atheroma volume 54 postoperative hemorrhage 54 steroid dexamethasone 54 p = #.# [003] 54 relapsed GBM 54 refractory NSCLC 54 COPD exacerbations 54 rFSH 54 smoldering multiple myeloma 54 AGHD 54 aminotransferases 54 mm Hg diastolic 54 symptomatic carotid stenosis 54 TAXUS Liberte Long 54 bicifadine 54 CANCIDAS 54 R0 resection 54 IV NSCLC 54 Visual Analogue Scale VAS 54 4mg/kg 54 P = .# 54 serum IGF 54 logistic regression models 54 ICD shocks 54 postvaccination 54 cytogenetic responses 54 endometrial carcinoma 54 CTEPH 54 undetectable viral loads 54 HBeAg positive 54 Pharmacokinetic 54 specific antigen PSA 54 advanced neoplasia 54 Telintra 54 ARB telmisartan 54 recurrent glioma 54 q#h 54 coinfected patients 54 sunitinib 54 CAMMS# 54 recurrent genital herpes 54 oral deforolimus 54 gadobutrol 54 oral allopurinol 54 pulmonary artery banding 54 neostigmine 54 pancreatic resection 53 serum creatinine levels 53 neoadjuvant chemotherapy 53 Hazard Ratio = 53 gp# vaccine 53 antiplatelet medication 53 serum phosphorus levels 53 cardiovascular hospitalizations